Yesterday’s announcement that the sole supplier of MOXATAG® had been placed into provisional liquidation (less than 8 months after Vernalis’ acquisition of the product) was disappointing. Although launch stock is available, we have removed the product from our FY’17 forecasts and pushed our forecasts for the anticipated US rollout out by one year (given the seasonal nature of prescriptions). In addition, we have ignificantly revised downwards our expectations for Vernalis’ cough cold franchise, ....
20 May 2016
MOXATAG® supply issue, forecast downgrade, moving to Hold
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
MOXATAG® supply issue, forecast downgrade, moving to Hold
Yesterday’s announcement that the sole supplier of MOXATAG® had been placed into provisional liquidation (less than 8 months after Vernalis’ acquisition of the product) was disappointing. Although launch stock is available, we have removed the product from our FY’17 forecasts and pushed our forecasts for the anticipated US rollout out by one year (given the seasonal nature of prescriptions). In addition, we have ignificantly revised downwards our expectations for Vernalis’ cough cold franchise, ....